Friday, July 10, 2026

pharma · Unresectable Hepatocellular Carcinoma (HCC) · Unexplained Recurrent Miscarriage and Recurrent Implantation Failure

Zenshine Pharmaceuticals

Zenshine Pharmaceuticals clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

CN HQ
2018 Founded
12 Employees
NMPA registrant Type
Company details
Status
Public
HQ
CN
Founded
2018
Employees
12
Programs
8
Drugs
17
Patents
0
Intelligence · Clinical Programs

Zenshine Pharmaceuticals projects

2 ClinicalTrials.gov programs sponsored by Zenshine Pharmaceuticals.

Zenshine Pharmaceuticals has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. RJK-RT2831 dose-escalation phase Ia

    Nanjing Zenshine Pharmaceuticals

    Hematologic Malignancies

    phase 1 small molecule active

    1 trial
  2. TQB2101 for Injection

    Nanjing Zenshine Pharmaceuticals

    Advanced Hematologic Malignancies

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Zenshine Pharmaceuticals have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.